PS
BMRN icon

Principal Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Principal Securities’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,599
Closed -$86.6K – 1603
2025
Q3 		$86.6K Buy
1,599
+30
+2% +$1.72K ﹤0.01% 1660
2025
Q2 		$86.2K Sell
1,569
-180
-10% -$10.6K ﹤0.01% 1608
2025
Q1 		$115K Hold
1,749
– – ﹤0.01% 1371
2024
Q4 		$115K Buy
1,749
+339
+24% +$22.7K ﹤0.01% 1371
2024
Q3 		$99.1K Sell
1,410
-24
-2% -$2.01K ﹤0.01% 1398
2024
Q2 		$118K Sell
1,434
-213
-13% -$17.7K ﹤0.01% 1252
2024
Q1 		$144K Sell
1,647
-57
-3% -$5.1K ﹤0.01% 1145
2023
Q4 		$164K Buy
+1,704
New +$151K 0.01% 997

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Principal Securities's BMRN Position: Q4 2025 in Review

Principal Securities sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 1,599 shares — an estimated $86.6K sold.

Principal Securities first reported a position in BMRN in Q4 2023 and held it in 8 quarters. The position peaked at $164K in Q4 2023. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • Principal Securities reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 1,599 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $86.6K.
  • Principal Securities first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Principal Securities's BioMarin Pharmaceuticals position peaked at $164K in Q4 2023.
  • 538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.